Recently, Prof. Dr. Saskia de Wildt, member of Radboud University, appeared on Regulatory Science Magazine sharing her views regarding the role of the Dutch Medicines Board (MEB) in paediatric research and in paediatric drug development.
Saskia de Wildt is a paediatric critical care specialist and a clinical pharmacologist working at RUMC in Nijmegen. She is a key figure within the Pharmacotherapy Improvement Cycle, which cares about improving medicines for children and making information available about the dosing of paediatric medicines. In this context, according to Dr. de Wildt EPTRI is a vital initiative to achieve this goal. “What’s the right way to set up such a medicine trial in children and what do you need to know about the biology of children, about preparing a formulation – a drink or a pill – how do you measure the effect, which biomarker do you use? The EPTRI project aims to provide support infrastructure for research that can answer all the latest questions. For instance, you cannot start a clinical examination if you have not got these things clear first. If nobody develops measures that you can use to assess pain in children, for example, you’ll have to continue to use the adult method. ”
In the same issue of the magazine we could also find an interview to Dr. Marjoom Pasmooij, Science Programme Manager of the MEB, who highlights the role of the board on the development of research projects. She finds knowledge transfer with the universities crucial to improve the delivery of better medicinal products, and that is why the MEB is involved in translational research projects, including EPTRI.